Australia markets open in 2 hours 35 minutes
  • ALL ORDS

    7,373.20
    -25.70 (-0.35%)
     
  • AUD/USD

    0.7109
    -0.0001 (-0.02%)
     
  • ASX 200

    7,128.80
    -20.10 (-0.28%)
     
  • OIL

    110.26
    -0.03 (-0.03%)
     
  • GOLD

    1,865.50
    +17.70 (+0.96%)
     
  • BTC-AUD

    41,494.18
    -79.64 (-0.19%)
     
  • CMC Crypto 200

    655.31
    -0.52 (-0.08%)
     

Independent Director Jon Lamb Just Bought 16% More Shares In AFT Pharmaceuticals Limited (NZSE:AFT)

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Investors who take an interest in AFT Pharmaceuticals Limited (NZSE:AFT) should definitely note that the Independent Director, Jon Lamb, recently paid NZ$4.20 per share to buy NZ$171k worth of the stock. That's a very decent purchase to our minds and it grew their holding by a solid 16%.

See our latest analysis for AFT Pharmaceuticals

The Last 12 Months Of Insider Transactions At AFT Pharmaceuticals

In fact, the recent purchase by Jon Lamb was the biggest purchase of AFT Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of NZ$4.38. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for AFT Pharmaceuticals share holders is that an insider was buying at near the current price. Jon Lamb was the only individual insider to buy during the last year.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

insider-trading-volume
insider-trading-volume

AFT Pharmaceuticals is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership of AFT Pharmaceuticals

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. AFT Pharmaceuticals insiders own about NZ$323m worth of shares (which is 71% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

What Might The Insider Transactions At AFT Pharmaceuticals Tell Us?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about AFT Pharmaceuticals. Looks promising! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 1 warning sign for AFT Pharmaceuticals and we suggest you have a look.

Of course AFT Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting